{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:46:35Z","timestamp":1791726395389,"version":"4.3.4"},"reference-count":113,"publisher":"SAABRON PRESS","issue":"3","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.46989\/001c.121404","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:06:04Z","timestamp":1727438764000},"source":"Crossref","is-referenced-by-count":8,"title":["Allogeneic and other innovative chimeric antigen receptor platforms"],"prefix":"10.46989","volume":"6","author":[{"given":"Andrew P","family":"Jallouk","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine, Hematology Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salyka","family":"Sengsayadeth","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine, Hematology Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N","family":"Savani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine, Hematology Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine, Hematology Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine, Hematology Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors","volume":"12","author":"C. Sloas","year":"2021","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.3390\/cells11223626","article-title":"Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors","volume":"11","author":"A. Cheever","year":"2022","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy","volume":"2","author":"M. Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"N. N. Shah","year":"2020","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s44222-023-00031-x","article-title":"Optimizing the manufacturing and antitumour response of CAR T therapy","volume":"1","author":"Y. Liu","year":"2023","journal-title":"Nat Rev Bioeng"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"S. Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development","author":"M. J. Dickinson","year":"2023","journal-title":"Cancer Discov"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/blood-2021-146268","article-title":"A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed\/Refractory (r\/r) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"138","author":"I. W. Flinn","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"ref9","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","article-title":"Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"A. S. Sperling","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","article-title":"Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells","volume":"40","author":"P. Agarwalla","year":"2022","journal-title":"Nat Biotechnol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"J. H. Park","year":"2023","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"W. Nawaz","year":"2021","journal-title":"Blood Cancer Journal"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes","volume":"28","author":"S. Agarwal","year":"2020","journal-title":"Mol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"J. G. Rurik","year":"2022","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"N. N. Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"bloodadvances.2023010653","DOI":"10.1182\/bloodadvances.2023010653","article-title":"A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma","author":"P. Strati","year":"2023","journal-title":"Blood Adv"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"L. Falchi","year":"2023","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hon.2858","article-title":"Bispecific antibodies for the treatment of lymphomas: Promises and challenges","volume":"39","author":"S. J. Schuster","year":"2021","journal-title":"Hematol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","author":"C. Thieblemont","year":"2022","journal-title":"J Clin Oncol JCO.22.01725"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"M. J. Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"S. S. Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"J. S. Abramson","year":"2020","journal-title":"The Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"S. Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/bjh.17904","article-title":"Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies","volume":"197","author":"B. Dhakal","year":"2022","journal-title":"Br J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"R. C. Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-023-00482-9","article-title":"New cell sources for CAR-based immunotherapy","volume":"11","author":"M. Mazinani","year":"2023","journal-title":"Biomark Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/trf.14365","article-title":"Cord blood-derived T cells allow the generation of a more na\u00efve tumor-reactive cytotoxic T-cell phenotype","volume":"58","author":"J. Kwoczek","year":"2018","journal-title":"Transfusion (Paris)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fonc.2022.944248","article-title":"Umbilical cord blood: A promising source for allogeneic CAR-T cells","volume":"22","author":"D.-D. Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"13","key":"ref29","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.3390\/cancers14133168","article-title":"Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells","volume":"14","author":"B. Ca\u00ebl","year":"2022","journal-title":"Cancers"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11899-019-00528-6","article-title":"Induced Pluripotent Stem Cell (iPSC)\u2013Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges","volume":"14","author":"A. Nianias","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"M. Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.stem.2023.02.004","article-title":"Unraveling barriers to iPSC-derived CAR-T cell differentiation","volume":"30","author":"S.J.C. Van Der Stegen","year":"2023","journal-title":"Cell Stem Cell"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell\u2013like properties","volume":"17","author":"L. Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"273ra13","DOI":"10.1126\/scitranslmed.3010314","article-title":"In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells","volume":"7","author":"L. Biasco","year":"2015","journal-title":"Sci Transl Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"N. Singh","year":"2016","journal-title":"Sci Transl Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"S. Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1182\/blood-2022-165311","article-title":"Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed\/Refractory B-Cell Lymphoma","volume":"140","author":"C. A. Jacobson","year":"2022","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/blood-2021-154034","article-title":"Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control","volume":"138","author":"H. Tseng","year":"2021","journal-title":"Blood"},{"issue":"7","key":"ref39","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/cells11071140","article-title":"Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies","volume":"11","author":"K. Beider","year":"2022","journal-title":"Cells"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1002\/acg2.86","article-title":"Toward \u201coff-the-shelf\u201d allogeneic CAR T cells","volume":"3","author":"B. T. Aftab","year":"2020","journal-title":"Adv CELL GENE Ther"},{"issue":"16_suppl","key":"ref41","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1200\/JCO.2023.41.16_suppl.2517","article-title":"Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL)","volume":"41","author":"F. L. Locke","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","author":"S. Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/01.HS9.0000848676.15840.df","article-title":"P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)","volume":"6","author":"L. J. Nastoupil","year":"2022","journal-title":"HemaSphere"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1182\/blood-2021-150609","article-title":"Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed\/Refractory B-Cell Malignancies","volume":"138","author":"B. D. Shah","year":"2021","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e1789302","DOI":"10.1097\/01.HS9.0000968336.17893.02","article-title":"P356: PHASE 1\/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R\/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA\/LYMPHOBLASTIC LYMPHOMA(T-ALL\/LBL)","volume":"7","author":"A. Ghobadi","year":"2023","journal-title":"HemaSphere"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.bbmt.2017.12.595","article-title":"Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder","volume":"24","author":"S. E. Prockop","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"L. Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"T. Haque","year":"2007","journal-title":"Blood"},{"issue":"15_suppl","key":"ref49","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2020.38.15_suppl.8002","article-title":"First-in-human data of ALLO-501 and ALLO-647 in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study","volume":"38","author":"S.S. Neelapu","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"B. D. Shah","year":"2021","journal-title":"The Lancet"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"J. J. Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key?","volume":"133","author":"S.S. Neelapu","year":"2019","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"A.V. Hirayama","year":"2019","journal-title":"Blood"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1038\/s41375-022-01704-z","article-title":"Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy","volume":"36","author":"P. Strati","year":"2022","journal-title":"Leukemia"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"M.D Jain","year":"2021","journal-title":"Blood"},{"issue":"15_suppl","key":"ref56","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2021.39.15_suppl.2527","article-title":"Safety and PK\/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)\/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy","volume":"39","author":"M. T. Tees","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood-2021-146045","article-title":"ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing","volume":"138","author":"L. J. Lekakis","year":"2021","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.18609\/cgti.2018.105","article-title":"Management of \u2018out of specification\u2019 commercial autologous CAR-T cell products","volume":"4","author":"A. Bersenev","year":"2018","journal-title":"Cell Gene Ther Insights"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"K. Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"618427","DOI":"10.3389\/fimmu.2020.618427","article-title":"Allogeneic CAR Cell Therapy\u2014More Than a Pipe Dream","volume":"11","author":"K. J. Caldwell","year":"2021","journal-title":"Front Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bbmt.2007.10.025","article-title":"Graft Failure after Allogeneic Hematopoietic Cell Transplantation","volume":"14","author":"J. Mattsson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.5966\/sctm.2015-0049","article-title":"Targeted Disruption of the \u03b22-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells","volume":"4","author":"D. Wang","year":"2015","journal-title":"STEM CELLS Transl Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1182\/blood-2019-131839","article-title":"Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-Bcma-ALLO1, Is Robust, Reproducible and Highly Scalable","volume":"134","author":"S. A. Cranert","year":"2019","journal-title":"Blood"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study","volume":"140","author":"J. P. McGuirk","year":"2022","journal-title":"Blood"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"G. G. Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/eji.202049107","article-title":"Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis","volume":"51","author":"Y. Guo","year":"2021","journal-title":"Eur J Immunol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1052717","article-title":"Simultaneous editing of TCR, HLA-I\/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection","volume":"13","author":"W. Li","year":"2022","journal-title":"Front Immunol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.117.306290","article-title":"Efficient Gene Disruption in Cultured Primary Human Endothelial Cells by CRISPR\/Cas9","volume":"117","author":"P. Abrahimi","year":"2015","journal-title":"Circ Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Q. Deng","year":"2020","journal-title":"Nat Med"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1182\/blood-2022-167627","article-title":"Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b","volume":"140","author":"C. Chaivorapol","year":"2022","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41587-022-01540-7","article-title":"Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression","volume":"41","author":"A. Gravina","year":"2023","journal-title":"Nat Biotechnol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"F. Mo","year":"2021","journal-title":"Nat Biotechnol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"CT011","DOI":"10.1158\/1538-7445.AM2023-CT011","article-title":"Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)","volume":"83","author":"S. Srour","year":"2023","journal-title":"Cancer Res"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41467-023-37785-2","article-title":"Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice","volume":"14","author":"X. Hu","year":"2023","journal-title":"Nat Commun"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"S. Jo","year":"2022","journal-title":"Nat Commun"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867013","article-title":"The Past, Present, and Future of Non-Viral CAR T Cells","volume":"13","author":"A. Moretti","year":"2022","journal-title":"Front Immunol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1093\/hmg\/ddr140","article-title":"The Sleeping Beauty transposon system: a non-viral vector for gene therapy","volume":"20","author":"E. L. Aronovich","year":"2011","journal-title":"Hum Mol Genet"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/sj.mt.6300028","article-title":"PiggyBac Transposon-mediated Gene Transfer in Human Cells","volume":"15","author":"M. H. Wilson","year":"2007","journal-title":"Mol Ther"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41434-020-0121-4","article-title":"Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion","volume":"27","author":"L. Chicaybam","year":"2020","journal-title":"Gene Ther"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"N. J. Haradhvala","year":"2022","journal-title":"Nat Med"},{"issue":"70","key":"ref81","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1182\/blood-2021-151672","article-title":"Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System","volume":"138","author":"C. Costello","year":"2021","journal-title":"Blood"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cellimm.2018.04.007","article-title":"Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer","volume":"329","author":"J. He","year":"2018","journal-title":"Cell Immunol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Y. Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"K. P. Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"J. Zhang","year":"2022","journal-title":"Nature"},{"issue":"e3066","key":"ref86","doi-asserted-by":"publisher","first-page":"e3066","DOI":"10.1002\/btpr.3066","article-title":"Optimization of electroporation and other non-viral gene delivery strategies for T cells","volume":"37","author":"E. Harris","year":"2021","journal-title":"Biotechnol Prog"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","article-title":"Polymer- and lipid-based gene delivery technology for CAR T cell therapy","volume":"353","author":"I. S. Pinto","year":"2023","journal-title":"J Controlled Release"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"107760","DOI":"10.1016\/j.biotechadv.2021.107760","article-title":"Non-viral transfection technologies for next-generation therapeutic T cell engineering","volume":"49","author":"L. Raes","year":"2021","journal-title":"Biotechnol Adv"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"W. Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"A. Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium","volume":"41","author":"Y. Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1182\/blood-2021-153150","article-title":"Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies","volume":"138","author":"T. Leedom","year":"2021","journal-title":"Blood"},{"key":"ref93","article-title":"Human Gene Therapy Products Incorporating Human Genome Editing","author":"Research C for BE and","year":"2022"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T Cells: More than Ease of Access?","volume":"7","author":"C. Graham","year":"2018","journal-title":"Cells"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ymthe.2022.12.004","article-title":"Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells","volume":"31","author":"B. J. Sasu","year":"2023","journal-title":"Mol Ther"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","author":"G. Xie","year":"2020","journal-title":"eBioMedicine"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity","volume":"193","author":"H. Rafei","year":"2021","journal-title":"Br J Haematol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"I. Prager","year":"2019","journal-title":"J Leukoc Biol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"12740","DOI":"10.1182\/blood-2022-158634","article-title":"A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R\/R) Acute Myeloid Leukemia (AML)","volume":"140","author":"A.F. Cashen","year":"2022","journal-title":"Blood"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"E. Liu","year":"2018","journal-title":"Leukemia"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00281-018-0721-x","article-title":"Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells","volume":"41","author":"M. L. Saetersmoen","year":"2019","journal-title":"Semin Immunopathol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"S. S. Neelapu","year":"2022","journal-title":"Nat Med"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"E. Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood-2021-151185","article-title":"Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed\/Refractory B-Cell Lymphoma","volume":"138","author":"V. Bachanova","year":"2021","journal-title":"Blood"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"TPS7580","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7580","article-title":"The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies","volume":"41","author":"K. Patel","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2020.11.003","article-title":"Memory-like natural killer cells for cancer immunotherapy","volume":"57","author":"M. Gang","year":"2020","journal-title":"Semin Hematol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1200\/JCO.2023.41.4_suppl.170","article-title":"WU-NK-101, an enhanced memory natural killer (NK) cell therapy, with cetuximab (Ctx) for the treatment of advanced colorectal cancer (CRC)","volume":"41","author":"J. Muth","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1016\/j.annonc.2022.07.039","article-title":"11P WU-NK-101: An enhanced NK cell therapy optimized for function in the tumor microenvironment (TME)","volume":"33","author":"S. Rutella","year":"2022","journal-title":"Ann Oncol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"334","DOI":"10.37349\/ei.2022.00054","article-title":"Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies","volume":"2","author":"N. Jhita","year":"2022","journal-title":"Explor Immunol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia","author":"M. Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1182\/blood-2022-157400","article-title":"A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (\u03b3\u03b4) T Cells in Adults with B-Cell Malignancies","volume":"140","author":"S. S. Neelapu","year":"2022","journal-title":"Blood"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"M. Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"10399","DOI":"10.1182\/blood-2022-156117","article-title":"Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed\/Refractory Large B-Cell Lymphoma (R\/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6","volume":"140","author":"O.O. Oluwole","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/121404-allogeneic-and-other-innovative-chimeric-antigen-receptor-platforms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:24:02Z","timestamp":1791725042000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/121404-allogeneic-and-other-innovative-chimeric-antigen-receptor-platforms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":113,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.121404","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}